MXPA04005156A - Antagonistas del receptor de adenosina a2a. - Google Patents

Antagonistas del receptor de adenosina a2a.

Info

Publication number
MXPA04005156A
MXPA04005156A MXPA04005156A MXPA04005156A MXPA04005156A MX PA04005156 A MXPA04005156 A MX PA04005156A MX PA04005156 A MXPA04005156 A MX PA04005156A MX PA04005156 A MXPA04005156 A MX PA04005156A MX PA04005156 A MXPA04005156 A MX PA04005156A
Authority
MX
Mexico
Prior art keywords
adenosine
solvates
administering
patient
compounds
Prior art date
Application number
MXPA04005156A
Other languages
English (en)
Spanish (es)
Inventor
Bernard R Neustadt
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA04005156A publication Critical patent/MXPA04005156A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MXPA04005156A 2001-11-30 2002-11-26 Antagonistas del receptor de adenosina a2a. MXPA04005156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33429301P 2001-11-30 2001-11-30
PCT/US2002/038134 WO2003048164A2 (en) 2001-11-30 2002-11-26 Adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA04005156A true MXPA04005156A (es) 2004-08-11

Family

ID=23306533

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005156A MXPA04005156A (es) 2001-11-30 2002-11-26 Antagonistas del receptor de adenosina a2a.

Country Status (18)

Country Link
US (1) US7041666B2 (enExample)
EP (1) EP1453835B1 (enExample)
JP (2) JP4284181B2 (enExample)
KR (1) KR20050044607A (enExample)
CN (1) CN1596258A (enExample)
AR (1) AR038366A1 (enExample)
AT (1) ATE317844T1 (enExample)
AU (1) AU2002346572A1 (enExample)
CA (1) CA2468681C (enExample)
DE (1) DE60209251T2 (enExample)
ES (1) ES2258164T3 (enExample)
HU (1) HUP0402270A3 (enExample)
IL (1) IL161572A0 (enExample)
MX (1) MXPA04005156A (enExample)
PE (1) PE20030739A1 (enExample)
TW (1) TW200300686A (enExample)
WO (1) WO2003048164A2 (enExample)
ZA (1) ZA200404160B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272886A1 (en) * 2002-09-24 2004-04-19 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
MXPA05006790A (es) 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
EP1618109A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
US7816353B2 (en) * 2003-10-24 2010-10-19 Exelixis, Inc. P70S6 kinase modulators and method of use
AR050926A1 (es) * 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
JP5366803B2 (ja) * 2007-05-24 2013-12-11 田辺三菱製薬株式会社 脳梗塞治療剤
US20110002855A1 (en) * 2007-06-25 2011-01-06 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
US20100093756A1 (en) * 2008-10-13 2010-04-15 Berbay J Kent HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093764A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
BRPI0921570A2 (pt) 2008-11-25 2019-09-24 Nissan Motor membro condutor de eletricidade e célula de combustível de eletrólito de polímero utilizando o mesmo
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cxcr3受容体アンタゴニスト
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
CN103261202B (zh) * 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
EP3611174B1 (en) * 2017-04-07 2022-06-08 Medshine Discovery Inc. [1,2,4]triazolo[1,5-c]pyrimidine derivative as a2a receptor inhibitor
AU2019227607C1 (en) * 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CN112105617B (zh) * 2018-04-28 2022-04-05 南京明德新药研发有限公司 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
US12414952B2 (en) * 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP2022507734A (ja) 2018-11-20 2022-01-18 メルク・シャープ・アンド・ドーム・コーポレーション 置換アミノトリアゾロピリミジン及びアミノトリアゾロピラジンアデノシン受容体アンタゴニスト、医薬組成物及びそれらの使用
AR117164A1 (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer
JP2022511778A (ja) 2018-11-30 2022-02-01 メルク・シャープ・アンド・ドーム・コーポレーション アデノシン受容体拮抗薬としての7-、8-及び10-置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
JP7414827B2 (ja) 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
WO2020128036A1 (en) * 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
TWI829857B (zh) * 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5565460A (en) 1993-07-27 1996-10-15 Kyowa Hakko Koygo Co., Ltd. Therapeutic purine agents for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
WO1998042711A1 (en) 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
KR20010087361A (ko) * 1998-09-22 2001-09-15 히라타 다다시 [1,2,4]트리아졸로[1,5-c]피리미딘 유도체
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
WO2002079204A1 (en) * 2001-03-28 2002-10-10 Kyowa Hakko Kogyo Co., Ltd. 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative
CA2468658C (en) 2001-11-30 2009-04-14 Schering Corporation [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
WO2003048164A2 (en) 2003-06-12
CN1596258A (zh) 2005-03-16
HUP0402270A2 (hu) 2005-02-28
PE20030739A1 (es) 2003-08-28
JP2005511698A (ja) 2005-04-28
DE60209251T2 (de) 2006-11-09
EP1453835B1 (en) 2006-02-15
DE60209251D1 (de) 2006-04-20
KR20050044607A (ko) 2005-05-12
HUP0402270A3 (en) 2008-09-29
CA2468681C (en) 2011-01-25
JP4284181B2 (ja) 2009-06-24
CA2468681A1 (en) 2003-06-12
WO2003048164A3 (en) 2003-10-16
IL161572A0 (en) 2004-09-27
EP1453835A2 (en) 2004-09-08
TW200300686A (en) 2003-06-16
US7041666B2 (en) 2006-05-09
JP2008303217A (ja) 2008-12-18
ATE317844T1 (de) 2006-03-15
ZA200404160B (en) 2005-04-08
US20030212080A1 (en) 2003-11-13
HK1064100A1 (en) 2005-01-21
ES2258164T3 (es) 2006-08-16
AR038366A1 (es) 2005-01-12
AU2002346572A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003048164A3 (en) Adenosine a2a receptor antagonists
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
ATE361287T1 (de) Neue indol-2-on derivate
MXPA04012965A (es) Inhibidores virales.
MXPA03005464A (es) Agentes antivirales.
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
GB0022438D0 (en) Organic Compounds
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
DE60318193D1 (en) Phenethanolaminderivate
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
CA2292359A1 (en) Novel azalides and methods of making same
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
PL342614A1 (en) Anticarcinogenic drugs
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios

Legal Events

Date Code Title Description
FG Grant or registration